

## New Clinical Trial Opportunity

- **MCI/Early Alzheimer's Disease**

*SiteRx is excited to announce the launch of a new clinical research study in partnership with Hoffmann-La Roche. Now available to all network providers*

### Clinical Trial Summary

- Gantenerumab is a large Phase 2 trial
- Broad patient population Presence of mild cognitive impairment or mild Alzheimer's Disease with MMSE > 22
- Medical tests Routine labs, MRI brain and amyloid PET scans are complementary for all patients

### Key Inclusion Criteria

- Can be taking AChEI or memantine medication but need stable dosage for past 3 months. Other medication needs to be stable for past 4 weeks
- MMSE score >22 and dementia rating global of 0.5 or 1.0
- Age range of 50-90

### Key Exclusion Criteria

- Evidence of other neurological conditions affecting cognition
- History of vascular dementia (>2 lacunar infarcts), schizophrenia, schizoaffective, or bipolar disorder
- Alcohol or substance use dependence in past 2 years
- Daily use of opioids, benzodiazepines, or neuroleptics
- Consider dosage changing memory or other medication is a top reason for disqualification, but patients can stay on medication throughout the trial

**Questions about Gantenerumab?**  
**Contact your Clinical Trial Advocate Today:**  
**[Hello@SiteRx.com](mailto:Hello@SiteRx.com)**



**Immediate  
Patient Need**

**100+**

Gantenerumab is among the largest actively recruiting phase II studies, targeting patients with early Alzheimer's Disease



**Patient Site  
Options**

SiteRx is launching Gantenerumab at multiple sites in core geographies, providing maximal convenience to interested patients